Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

A complement inhibitor, patient technology, applied in the direction of drugs or prescriptions, drug reference, pump control, etc., can solve the problem of high infection complications
CN104205155AInactive Publication Date: 2014-12-10ALEXION PHARMA INC
7 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Current Assignee / Owner
ALEXION PHARMA INC
Publication Date
2014-12-10
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment. The information in the database is collected and may be reported. The patients are given a warning as to adverse events that may occur if treatment with the complement inhibiting drugs is discontinued.
Need to check novelty before this filing date? Find Prior Art

Description

technical field Background technique

[0001] Complement is an essential component of the immune system and has important relevance for the destruction of invading microorganisms and for maintaining tissue homeostasis including protection against autoimmune disease. However, excessive or uncontrolled complement activation contributes significantly to unwanted tissue damage. Complement activation presents a considerable risk of harming the host by directly and indirectly mediating inflammatory tissue destruction. Clinical and experimental evidence emphasizes the prominent role of complement in the pathogenesis of numerous inflammatory diseases.

[0002] In recent years, significant progress has been made in inhibiting complement activation as a potential treatment for complement-associated diseases. Some degree of inhibition of complement activation may be sufficient to reduce its deleterious effects, yet preserve defense mechanisms against invading pathogens. Redundancy of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More